Memo Therapeutics AG Entered into a Research and Development Collaboration Agreement with Ono to Discover Antibodies Against Immuno-Oncology Targets
Shots:
- MTx to receive an up front & research funding and is also eligible to receive clinical development and sales milestones along with royalties on future sales
- Ono to get an intellectual property right & an exclusive right globally to develop and commercialize therapeutic drug candidates with Abs under collaboration with Ono
- The collaboration enables MTx to use its microfluidic single-cell molecular cloning and screening technologies to discover Abs for immuno-oncology targets. The current pipeline of the company includes programs in infectious diseases and immuno-oncology
Ref: Businesswire | Image: Ono
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
